278 related articles for article (PubMed ID: 34627426)
21. [Multicenter evaluation of minimal residual disease monitoring in early induction therapy for treatment of childhood acute lymphoblastic leukemia].
Wu XJ; Liao N; Mai HR; Li XY; Wan WQ; Yang LH; Huang LB; Luo XQ; Tian C; Chen QW; Long XJ; He YY; Wang Y; Li ZG; Xu HG
Zhonghua Er Ke Za Zhi; 2024 Mar; 62(4):337-344. PubMed ID: 38527504
[No Abstract] [Full Text] [Related]
22. Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
Li XY; Li JQ; Luo XQ; Wu XD; Sun X; Xu HG; Li CG; Liu RY; Sun XF; Chen HQ; Lin YD; Li CK; Fang JP
BMC Cancer; 2021 Jan; 21(1):59. PubMed ID: 33435902
[TBL] [Abstract][Full Text] [Related]
23. [Prognostic Significance of Joint Detection of miR-210 and Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia].
Mei YY; Li ZG; Zhang Y; Zhang WL; Zhang PW; Wang N; Huang DS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):66-71. PubMed ID: 28245377
[TBL] [Abstract][Full Text] [Related]
24. [Outcome of childhood T-cell acute lymphoblastic leukemia: a report of 99 cases].
Cai JY; Xue HL; Chen J; Shen SH; Pan C; Wang X; Zhou M; Tang YJ; Gao YJ; Wang JM; Tang JY
Zhonghua Er Ke Za Zhi; 2016 Jun; 54(6):456-60. PubMed ID: 27256235
[TBL] [Abstract][Full Text] [Related]
25. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Jabbour E; Short NJ; Jorgensen JL; Yilmaz M; Ravandi F; Wang SA; Thomas DA; Khoury J; Champlin RE; Khouri I; Kebriaei P; O'Brien SM; Garcia-Manero G; Cortes JE; Sasaki K; Dinardo CD; Kadia TM; Jain N; Konopleva M; Garris R; Kantarjian HM
Cancer; 2017 Jan; 123(2):294-302. PubMed ID: 27602508
[TBL] [Abstract][Full Text] [Related]
26. Clinical Analysis of Pediatric T-Cell Acute Lymphoblastic Leukemia Using the MRD-Oriented Strategy System.
Xue YJ; Wang Y; Lu AD; Jia YP; Zuo YX; Ding MM; Zeng HM; Zhang LP
Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):477-483. PubMed ID: 37080879
[TBL] [Abstract][Full Text] [Related]
27. [Prognostic significance and risk factors of minimal residual disease ≥1% on 19th day of induction chemotherapy in children with acute lymphoblastic leukemia].
Yu J; Yi T; Lin G; Wen J; Chen L; Chen J; Wu X
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Feb; 40(2):255-261. PubMed ID: 32376526
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of Adults with Acute Lymphoblastic Leukemia After Autologous Hematopoietic Stem Cell Transplantation and the Significance of Pretransplantation Minimal Residual Disease: Analysis from a Single Center of China.
Ding Z; Han MZ; Chen SL; Ma QL; Wei JL; Pang AM; Zhang XY; Liang C; Yao JF; Cao YG; Feng SZ; Jiang EL
Chin Med J (Engl); 2015 Aug; 128(15):2065-71. PubMed ID: 26228220
[TBL] [Abstract][Full Text] [Related]
29. [Comparison of the efficacy of two chemotherapy protocols for children with TEL-AML1[STBZ] fusion gene positive acute lymphoblastic leukemia].
Wang KL; Mei YY; Cui L; Gao C; Liu FF; Zhao XX; Li WJ; Jiang J; Zhang RD; Xie J; Shi HW; Wang B; Zhang YH; Ma XL; Wu MY; Zhou X; Li ZG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):285-90. PubMed ID: 24762993
[TBL] [Abstract][Full Text] [Related]
30. [Prognostic Value of Prednisone Response in CCLG-ALL 2008].
Ren YY; Zou Y; Chang LX; An WB; Wan Y; Zhang JL; Liu TF; Zhu XF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Jun; 23(3):642-6. PubMed ID: 26117009
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
[TBL] [Abstract][Full Text] [Related]
32. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
[TBL] [Abstract][Full Text] [Related]
33. [The Factors Affecting Relapse in Pediatric B-cell Acute Lymphoblastic Leukemia Patients without Prognostic Fusion Genes Following Up for 10 years].
Jiang MY; Gao W; Gao J; Ling J; Pan J; Xiao PF; Lu J; He HL; Wang Y; Li J; Li JQ; Chai YH; Sun YN; Hu SY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):12-17. PubMed ID: 35123597
[TBL] [Abstract][Full Text] [Related]
34. PH negative acute lymphoblastic leukemia in adolescents and young adults treated according a MRD adapted BFM ALL IC 2009 protocol: Argentine real-world data on 171 patients.
Ferrari LC; Rivas MM; Navickas AB; Dick H; Mela Osorio MJ; Agamennoni L; Rey IH; Carnelutto NE; Cazap N; Castro MB; Aranguren PN; Fischman LA; Yupanki ML; Milone JH; Fernández II; Moirano MM; Belli CB;
Ann Hematol; 2023 May; 102(5):1087-1097. PubMed ID: 36892593
[TBL] [Abstract][Full Text] [Related]
35. Assessment of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: A Multicenter Study From Turkey.
Tüfekçi Ö; Evim MS; Güneş AM; Celkan T; Karapinar DY; Kaya Z; Baysal B; Baytan B; Koçak Ü; Yilmaz Ş; Çinar S; Ören H
J Pediatr Hematol Oncol; 2022 Mar; 44(2):e396-e402. PubMed ID: 35129146
[TBL] [Abstract][Full Text] [Related]
36. Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: A Clinical Evidence Review.
Health Quality Ontario
Ont Health Technol Assess Ser; 2016; 16(7):1-52. PubMed ID: 27099643
[TBL] [Abstract][Full Text] [Related]
37. Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group.
Pieters R; de Groot-Kruseman H; Van der Velden V; Fiocco M; van den Berg H; de Bont E; Egeler RM; Hoogerbrugge P; Kaspers G; Van der Schoot E; De Haas V; Van Dongen J
J Clin Oncol; 2016 Aug; 34(22):2591-601. PubMed ID: 27269950
[TBL] [Abstract][Full Text] [Related]
38. Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: The first nation-wide prospective multicenter study in China.
Cui L; Li ZG; Chai YH; Yu J; Gao J; Zhu XF; Jin RM; Shi XD; Zhang LP; Gao YJ; Zhang RD; Zheng HY; Hu SY; Cui YH; Zhu YP; Zou Y; Ng MHL; Xiao Y; Li JH; Zhang YH; He HL; Xian Y; Wang TY; Li CK; Wu MY;
Am J Hematol; 2018 Jul; 93(7):913-920. PubMed ID: 29675840
[TBL] [Abstract][Full Text] [Related]
39. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.
Bader P; Kreyenberg H; von Stackelberg A; Eckert C; Salzmann-Manrique E; Meisel R; Poetschger U; Stachel D; Schrappe M; Alten J; Schrauder A; Schulz A; Lang P; Müller I; Albert MH; Willasch AM; Klingebiel TE; Peters C
J Clin Oncol; 2015 Apr; 33(11):1275-84. PubMed ID: 25605857
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of
Yuan Y; Li J; Xue TL; Hu HR; Lin W; Liu SG; Zhang RD; Zheng HY; Gao C
Leuk Lymphoma; 2022 Jul; 63(7):1624-1633. PubMed ID: 35129045
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
